What's moving the markets on Monday?

The FTSE, along with its European peer are heading for a higher start boosted by vaccine optimism and ahead of a key day in Parliament for the Internal Markets Bill.

Charts (2)

The FTSE, along with its European peer are heading for a higher start boosted by vaccine optimism and ahead of a key day in Parliament for the Internal Markets Bill.

Vaccine trials restart
Over the weekend, Oxford University announced that the joint AstraZeneca covid vaccine trial will restart this week after a routine pause n the previous week. News that the trial is back on track is music to the ears of the market. A vaccine is the surest and quickest, and possibly the only way for the economy to recover to pre-pandemic growth levels. The vaccine news comes as the “Rule of 6” comes into force in the UK, banning meetings of groups of over 6. AstraZeneca shares are on the rise in early trade. 
Adding to the upbeat vaccine news Pfizer In Chief executive officer Albert Bourla said its likely that a covid vaccine will be deployed in the US by the end of the year. A more optimistic view than health authorities. 

Internal Markets Bill debate
Markets and the Pound are braced for another big Brexit week. The controversial internal markets bill will start to be discussed today in the House of Commons. It is not certain whether the bill will make it through the Commons or even the Lords given that it breaks international law. However, if it does clear Parliaments the Justice Secretary Robert Buckland has already said he will resign. The Pound was the worst performer across the previous week, shedding 3.7% versus the USD in its worst weekly performance since early March. GBP is one of the of performing majors this morning ahead of the debate.

Whilst the 8th round of Brexit talks ended with unsurprisingly little progress, informal Brexit talks are set to continue across the week, ahead of the 9th round beginning on 25th September.

TikTok to partner Oracle, Nvidia buys ARM
Rumours are swirling that TiKTok is choosing to partner up with Oracle rather than Microsoft. Microsoft hasn’t been asked to revise its initial offer amid opposition to the deal from the Chinese government. Has Microsoft managed to dodge a bullet? Could be so according to Bloomberg reports that the deal no longer includes key underlying technologies and the prospect of Chinese government approval is unclear at best.

Nvidia has agreed to buy ARM Holding, SoftBank’s chip division for $40 billion 4 years after the Japanese bank bought it for $32 billion.

Eurozone industrial production
Looking ahead, Eurozone industrial production data will provide some clues as to the health of the sector. Expectations are for growth 10% mom in July, up from 9.1% in June as the sector outperforms services in its recovery. 

FTSE Chart
The FTSE is continuing its rebound from Sept 3rd lows, pishing above 50,100 and 200 sma on 4 hr chart. Immediate resistance can be seen at 6110 prior to 6180 (high 25th Aug).
Support can be seen at 6030 200 sma, prior to 5980 (100sma).



More from FTSE 100

From time to time, GAIN Capital Australia Pty Ltd (“we”, “our”) website may contain links to other sites and/or resources provided by third parties. These links and/or resources are provided for your information only and we have no control over the contents of those materials, and in no way endorse their content. Any analysis, opinion, commentary or research-based material on our website is for information and educational purposes only and is not, in any circumstances, intended to be an offer, recommendation or solicitation to buy or sell. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. No representation or warranty is made, express or implied, that the materials on our website are complete or accurate. We are not under any obligation to update any such material.

As such, we (and/or our associated companies) will not be responsible or liable for any loss or damage incurred by you or any third party arising out of, or in connection with, any use of the information on our website (other than with regards to any duty or liability that we are unable to limit or exclude by law or under the applicable regulatory system) and any such liability is hereby expressly disclaimed.